Published in ACS Med Chem Lett on August 26, 2016
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol (2008) 5.54
Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol (2003) 2.75
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood (2013) 2.26
The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol (2012) 2.06
Antibody-drug conjugates: an emerging concept in cancer therapy. Angew Chem Int Ed Engl (2014) 2.01
gem-disubstituent effect: theoretical basis and synthetic applications. Chem Rev (2005) 1.99
Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem (2006) 1.96
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res (2006) 1.67
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res (2011) 1.66
Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res (2010) 1.63
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med (2015) 1.33
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res (2011) 1.32
A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem (2013) 1.23
Pyrrol[1,4]benzodiazepine antibiotics. Proposed structures and characteristics of the in vitro deoxyribonucleic acid adducts of anthramycin, tomaymycin, sibiromycin, and neothramycins A and B. Biochemistry (1981) 1.07
The development of pyrrolobenzodiazepines as antitumour agents. Expert Opin Investig Drugs (2011) 1.06
The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links. J Am Chem Soc (2009) 1.05
ADME of antibody-maytansinoid conjugates. AAPS J (2012) 1.03
Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia (2010) 1.01
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J (2015) 0.96
Current ADC Linker Chemistry. Pharm Res (2015) 0.92
Structure of a covalent DNA minor groove adduct with a pyrrolobenzodiazepine dimer: evidence for sequence-specific interstrand cross-linking. J Med Chem (1994) 0.90
Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers. Nucleic Acids Res (2011) 0.89
Disulfide-containing parenteral delivery systems and their redox-biological fate. J Control Release (2014) 0.83
Effect of hairpin loop structure on reactivity, sequence preference and adduct orientation of a DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agent. Org Biomol Chem (2015) 0.78
Chemical Structure and Concentration of Intratumor Catabolites Determine Efficacy of Antibody Drug Conjugates. Drug Metab Dispos (2016) 0.78